Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Operating Leases (2019 - 2025)

Voyager Therapeutics' Operating Leases history spans 7 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 21.48% year-over-year to $28.7 million; the TTM value through Dec 2025 reached $28.7 million, down 21.48%, while the annual FY2025 figure was $28.7 million, 21.48% down from the prior year.
  • Operating Leases for Q4 2025 was $28.7 million at Voyager Therapeutics, down from $30.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $42.1 million in Q1 2021 and bottomed at $17.1 million in Q4 2023.
  • The 5-year median for Operating Leases is $33.6 million (2025), against an average of $30.9 million.
  • The largest annual shift saw Operating Leases plummeted 47.45% in 2022 before it soared 115.13% in 2024.
  • A 5-year view of Operating Leases shows it stood at $38.6 million in 2021, then tumbled by 47.44% to $20.3 million in 2022, then fell by 15.77% to $17.1 million in 2023, then soared by 113.52% to $36.5 million in 2024, then decreased by 21.48% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Operating Leases are $28.7 million (Q4 2025), $30.5 million (Q3 2025), and $32.6 million (Q2 2025).